Vital Art and Science Inc. (VAS), creator of the myVisionTrack home vision monitor, has completed a $550,000 Series A round of financing, the Richardson-based company announced Aug. 27.
The funding will enable VAS to continue development of its smart phone-based home monitor products and support its work with strategic partners to bring the myVisionTrack test to millions of patients around the world. The funding round was led by the North Texas Angel Network (NTAN), and valued the company at $10 million post financing.
“The myVisionTrack home monitor is the first easy-to-use and accurate test for patients already diagnosed with a wet-AMD, or diabetic retinopathy, to monitor their disease progress and help ensure they get timely treatments to help save their vision,” said Mike Bartlett, VAS founder and president.
Bartlett said the company received its clearance from the U.S. Food and Drug Administration in February. The funding will allow VAS, a client of technology incubator TECH Fort Worth, to bring its product to market. MyVisionTrack can be used in a physician’s office or at home by patients with these diseases to help track disease progression, detect disease condition changes for earlier intervention and document treatment effects.